The evidence on whether treatment increases cancer risk — broken down by which hormone, which woman, and which study.
A 1-minute view of what this section covers. Tap any item to read the full discussion.
Incidence (who develops cancer), full-cohort BC mortality (who dies from it), survival after diagnosis (collider-biased), and all-cause mortality (net neutral at 18 years) each have different answers by formulation and population.
Read full discussion →Finnish nationwide data (357,928 users, 13M person-years, median detection year 2011) found all systemic regimens elevated. Dydrogesterone-EPT was lowest but still elevated. Risk persisted 5-10 years after cessation for most regimens.
Read full discussion →Less than half of those who received treatment found it effective. Post-cancer GSM treatment evidence is mostly limited or uncertain across vaginal prasterone, laser, and ospemifene.
Read full discussion →A UK registry of 49,237 BC patients found no increased BC mortality with vaginal estrogen. A Danish study found a small recurrence increase specifically in AI users. These findings sit together.
Read full discussion →This is one of the most emotionally charged questions about hormone therapy. The evidence answers it with formulation-specific, endpoint-specific, and population-specific precision — which means the answer is not a simple yes or no.
The breast cancer and hormone therapy literature uses overlapping language for what are actually four distinct questions. Blending them leads to confusion.
1. Breast cancer incidence — Among women who do not have cancer, who develops it? This is what most studies measure. Combined estrogen-plus-progestogen therapy carries the clearest and most consistent signal for increased incidence. Estrogen-only therapy and tibolone vary more by trial, dataset, duration, and population.
2. Breast cancer-specific mortality in the full initially cancer-free cohort — Among all women who started hormone therapy, how many die from breast cancer? This is a different question with a different answer. In the NOWAC Norwegian prospective cohort, current estrogen-plus-progestogen therapy was associated with doubled luminal A-like breast cancer mortality (HR 2.15). In the WHI trial, oral conjugated estrogen alone in hysterectomized women was associated with reduced breast cancer mortality (HR 0.60) (45, 10).
3. Survival among diagnosed breast cancer patients — Of women who develop breast cancer, how many survive 5 or 10 years? This is where observational data consistently show that pre-diagnostic hormone therapy users look "better." But this signal is affected by multiple biases: collider/index-event bias, healthy-user bias, screening and detection bias (HT users get more mammograms and are diagnosed at earlier stages), and tumor-subtype favorability (HT-associated cancers tend to be lower-grade with better baseline prognosis). These survival findings do not support the conclusion that hormone therapy improves breast cancer survival or is safe after diagnosis.
4. All-cause mortality — The ultimate net-effect outcome. In the WHI 18-year follow-up (n=27,347, over 98% mortality capture), neither nor significantly changed all-cause mortality (pooled HR 0.99). Hormone therapy changes which outcomes are affected, not the total (2).
In the same WHI program, CEE plus medroxyprogesterone acetate in women with intact uterus increased breast cancer incidence (HR 1.28, 95% CI 1.13-1.45). The increase became significant at year 6 and persisted at least a decade after stopping. Breast cancer mortality trended higher but was not statistically significant (HR 1.35, 95% CI 0.94-1.95) (10).
The evidence above describes hormone therapy risk in women who have not had cancer. If you have a breast cancer history, the decision environment is different.
The unmet need is real. In a community survey of breast cancer survivors 6 years after diagnosis (n=385), 90% reported VMS or sleep disturbance, 75% vaginal dryness, 62% mood swings, and 59% sexual difficulties. Less than one-third were offered treatment, and less than half of those treated found it effective (35).
The Hickey Lancet 2024 cancer-survivor framework frames systemic MHT as generally not recommended after breast cancer, especially ER-positive disease, with careful exceptions considered only when quality of life is substantially affected and disease risk is low, through shared decision-making with the oncology team. The framework is cancer-type-specific, age-specific, and route-specific — transdermal MHT is preferred over oral in cancer patients due to elevated VTE risk (35).
The strongest post-BC systemic MHT evidence comes from two terminated RCTs that disagree. The HABITS trial (-based regimens) was terminated early after finding a 3.5-fold increased risk of new breast cancer events with MHT (26/174 MHT vs 7/171 control, adjusted HR 3.5). The Stockholm trial (-based regimens) found no increased recurrence risk (HR 0.82). The discrepancy is likely explained by lower-risk patients in Stockholm (16% vs 26% node-positive), more tamoxifen use (52% vs 21%), a different progestin, and lower progestin exposure (88). The conflict between these two trials is why post-diagnosis systemic MHT is a fundamentally different decision from population-level MHT risk assessment.
Vaginal estrogen after breast cancer has growing safety evidence. A meta-analysis of 8 observational studies found no increased recurrence, breast-cancer-specific mortality, or overall mortality with vaginal estrogen after breast cancer (follow-up up to 15.2 years) (88). Separately, a 2024 UK registry study of 49,237 breast cancer patients aged 40-79 found no evidence of increased breast cancer mortality with vaginal estrogen use. However, a 2022 Danish data linkage study found a small increase in recurrence among patients on adjuvant aromatase inhibitors using vaginal estrogen, with no worse survival. These two findings sit together: mortality reassurance does not mean no recurrence concern in every subgroup, particularly for AI users. Ultra-low doses minimize systemic absorption (35).
Systemic estrogen plus aromatase inhibitor is counterproductive — the cited expert panel reached 100% agreement on this point (88).
Post-cancer GSM treatment evidence is mostly limited or uncertain. Vaginal prasterone showed no benefit versus vaginal moisturizer in one RCT (n=464). Vaginal CO2 laser showed no benefit over sham in two controlled trials. Ospemifene's regulatory status after breast cancer differs by jurisdiction: the EMA permits it after completed breast cancer treatment, while the FDA considers it contraindicated (not adequately studied in breast cancer populations). Efficacy and safety specifically after cancer remain uncertain in the published evidence. CBT improved sexual function, desire, arousal, lubrication, and reduced distress in one RCT — among the strongest non-hormonal signals for this population (35).
Body-identical progesterone has not been shown to increase breast cancer risk for up to 5 years in observational data (MISSION RR 0.91). Beyond 5 years, the E3N cohort found elevated risk (HR 1.31), but could not distinguish progesterone from dydrogesterone and 57% of participants also used synthetic progestin (88). At the tissue level, a short prospective trial (n=77, 2 months) found that did not increase Ki-67, bcl-2, or mammographic density, while CEE plus MPA did — marker evidence, not incidence evidence (88).
LNG-IUS carries a small increased breast cancer risk in the general population — 14 additional cases per 10,000 women over 0-5 years — while reducing ovarian and endometrial cancer risk. Data in breast cancer survivors are insufficient (88).
shows an observational signal of lower breast cancer risk (RR 0.48, 0.37-0.62), with androgen receptor agonists antagonizing estrogen-stimulated tumor growth in preclinical work. Long-term safety data in breast cancer survivors do not exist (88).